Pediatrix Medical Group Q1 2025 Earnings Report

Pediatrix Medical Group EPS Results

• Actual EPS: $0.33
• Consensus EPS: $0.25
• Beat/Miss: Beat by +$0.08
• One Year Ago EPS: $0.20

Pediatrix Medical Group Revenue Results

• Actual Revenue: $458.36 million
• Expected Revenue: $451.44 million
• Beat/Miss: Beat by +$6.91 million
• YoY Revenue Growth: -7.40%

Pediatrix Medical Group Announcement Details

• Quarter: Q1 2025
• Date: 5/6/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 6, 2025
• Conference Call Time: 9:00AM ET

Pediatrix Medical Group (NYSE:MD) (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings. Pediatrix partners with hospitals, health systems and other healthcare providers across the United States to manage patient care programs, optimize clinical outcomes and support operational efficiencies. The company’s telehealth initiatives extend critical care expertise to remote and underserved locations while its research division advances evidence-based practices in neonatal and maternal-fetal medicine.

Under the leadership of President and CEO David R. Anderson, Pediatrix Medical Group emphasizes clinical quality, patient safety and physician engagement. The group supports more than 3,500 physicians and advanced practice clinicians and collaborates with over 1,300 facilities nationwide. Pediatrix continues to invest in clinical education, data analytics and population health management to meet the evolving needs of mothers, newborns and pediatric patients.

Pediatrix Medical Group Q1 2025 Earnings Call Transcript

Key Takeaways

• First quarter saw same unit revenue growth exceeding 6% and adjusted EBITDA of $49M outperformed expectations driven by strong NICU volumes and favorable payer mix.
• Management raised full‐year 2025 adjusted EBITDA guidance to $220–$240M from $215–$235M, maintaining a conservative stance due to ongoing healthcare and economic uncertainties.
• Overall consolidated revenue declined just over 7% as non‐same unit activity dropped $63M following 2024 portfolio restructuring, partially offset by same unit growth.
• Operating cash usage improved slightly to $116M in Q1 (versus $123M prior year), with DSO reduced to 48 days, ending the quarter with $99M cash and net debt of $512M (2.2× leverage).
• Company is reinvigorating hospital partnerships and has contracted acquisitions of several NICU, MFM, and OB hospitalist operations, reflecting momentum in its core specialty services.

Presentation

[Operator]

Certain statements and information during this conference call may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions and assessments made by Pediatrix management in light of their experience and assessment of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statements made during this call are made as of today, and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the company filing with the SEC, including the sections entitled Risk Factors. In case remarks by management, we will be discussing non-GAAP financial metrics.

[Operator]

A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures can be found in the morning's earnings press release, our quarterly and annual reports, and on our website, at www.pediatrix.com. With that, I will turn the call over to Mark Ordan, Pediatrix Medical Group's Chief Executive Officer.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Thank you, Operator. Good morning, everyone. With me today is Kasandra Rossi, our Chief Financial Officer. Our first quarter results exceeded our expectations, driven by same-unit revenue growth of over 6%. This included strong volumes in our hospital-based services, with NICU days increasing by 2%, as well as more modest growth in maternal-fetal medicine, along with continued favorable paramedics. Our practice-level operating expenses continue to reflect the favorable impacts of our cost management initiatives, partially offset by higher incentive compensation based on our strong financial practice results. As a result, adjusted EBITDA of just over $49 million was significantly above our expectations. I'm particularly pleased with the continued sharp focus on same-unit salary expense trends that decelerated for the fourth consecutive quarter.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

As a result of our strong financial performance for the first quarter compared to our expectations, we are raising our full-year 2025 adjusted EBITDA outlook from a range of $215 million-$235 million to a range of $220 million-$240 million. While we are pleased by our first quarter results, we remain mindful that we continue to be in a period of great uncertainty, both in healthcare and throughout the economy. Our operating results for the first quarter include the effectiveness of our strategic approach to the portfolio management activities that we completed in 2024 and our commitment to creating value for our shareholders. This is a direct result of the hard work, collaboration, and dedication of our team, and we're excited to build upon these results.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

In February, I talked about our strategic priorities in 2025 and, in particular, our focus on methodically reinvigorating the relationships that we have built over many years with our hospital and health system partners. I also spoke about all we are doing reasonably to be the employer of choice for physicians and other clinicians who provide the extraordinary critical care our patients require. I'm very pleased to report that I, along with our operating leadership team, are actively engaged here, and we are pleased with the early response. We recently contracted to acquire several NICU, MFM, and OB hospital operations that are part of a hospital system's portfolio because we believe that that system views us as the best and most reliable partner in these areas. I believe this is directly tied to our renewed active engagement both with our practices and with hospital system leadership.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

We won't win every opportunity, and at times hospitals choose to bring things in-house, but we are hard at work to be the best and most responsive partner possible. At Pediatrix, we are our people, the women and men who provide the finest possible clinical care in a very difficult area. Here too, we are very actively focused on our recruiting, onboarding, development, and retention efforts. We are confident that this focus will meaningfully bolster our core. If this blocking and tackling strategic focus sounds a bit boring to you, you're probably getting my point. Pediatrix has always been at its best when we are focused passionately on our core, and that is exactly where we are today. This is now providing growth opportunities for us, and we believe strongly this will continue. With that, I will turn the call over to Kasandra.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Thank you, Mark, and good morning, everyone. I'll provide some additional details in a few areas. Our consolidated revenue decreased by just over 7%, driven by non-same-unit activity, which declined by about $63 million, primarily related to the impacts from our portfolio restructuring activity. This decrease was partially offset by strong same-unit growth of over 6%. Same-unit pricing was up over 4.6%, driven by favorable payer mix shifts and modest improvements in contract administrative fees. This was combined with favorable impacts from strong RCM cash collections. On the cost side, practice-level SW&B expenses declined year over year, also reflecting our portfolio restructuring activity. On a same-unit basis, these expenses did increase year over year, but the increase was primarily related to higher incentive compensation based on strong practice results as well as salary increases.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Importantly, salary growth decelerated significantly year over year and on a sequential quarter basis as compared to the second, third, and fourth quarters of 2024. Our G&A expense decreased modestly year over year, primarily reflecting the favorable impacts from the staffing reductions across shared services that were completed in the prior year, partially offset by increases in other expenses, including billing and collection fees, certain professional services, and information technology. Depreciation and amortization expense declined to $5.3 million as compared to $10.3 million in the prior year, primarily reflecting the impacts of the practice dispositions. We expect our D&A expense will be fairly consistent going forward. Other expense was $4 million as compared to $8.1 million for the prior year period, primarily reflecting an increase in interest income on cash balances, as well as a decrease in interest expense on lower average borrowings at slightly lower rates.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Moving on to cash flow. As a reminder, we are a user of cash in the first quarter of each year as we pay out incentive compensation and other benefits, namely 401(k) matching contributions. We used $116 million in operating cash in the first quarter compared to $123 million in the prior year. The differential was primarily due to higher earnings and increases in cash flow from AR, partially offset by decreases in cash flow from accounts payable and accrued expenses, primarily related to those incentive compensation payments. We ended the quarter with cash of $99 million and net debt of $512 million. This reflects net leverage of just over 2.2 times using the midpoint of our updated adjusted EBITDA outlook range for 2025.

[Operator]

Our accounts receivable DSO of just under 48 days were flat as compared to December 31, but down over four days year over year, primarily related to improved cash collections at our existing units. Finally, I'll briefly touch on our updated 2025 outlook, noting that the increase was predominantly related to the top-line revenue growth achieved during first quarter versus our expectations. The comps for the remainder of 2025 become increasingly challenging and accordingly remain materially in line with our original 2025 expectations. With that, I will turn the call back over to Mark.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Thanks, Kasandra. Operator, we'll now open the call for questions.

[Operator]

Thank you. We will now begin the question and answer session. At this time, I would like to remind everyone, in order to ask a question, press star, then the number one on your telephone keypad. We will pause for just a moment to compile the Q&A roster. Your first question comes from the line of A.J. Rice with UBS. Your line is open.

[A.J. Rice, Managing Director at UBS]

Thanks. Hi, everybody. Maybe just on the updated thoughts on guidance. I know coming into the year, I think the basic base case was flat volumes and flat pricing for the year. Obviously, you were up 1.6% on volumes and 4.6% on pricing in the first quarter. I know you're saying comps get tougher, but does the flat pricing and flat volumes look conservative in light of what you've seen so far this year?

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

When we gave our initial guidance, we said we were intentionally being a little bit on the conservative side given the uncertainty that prevailed. Since that uncertainty has probably only accentuated in healthcare and around the economy, we continue to have a conservative stance. It's simply that the first quarter, A.J., exceeded our expectations by enough that we said it doesn't make mathematical sense to stay at the old level. Certainly, the amount of EBITDA that we already have in the till is what gave rise to the increase. Is it still conservative? I think only for the same reason as it was before. We still see headwinds in healthcare and the uncertainty in the economy, but that's why we raised it as we did.

[A.J. Rice, Managing Director at UBS]

Just speaking to that uncertainty, I know to some degree people can make decisions about expanding a family based on what's happening in the economy. Is that what you're mainly talking about when you look at the things that they're specifically looking at in Washington around budget reconciliation? I wouldn't assume that those were addressing changes with the expansion population, et cetera, some things that would potentially, I guess, limit supplemental payments, which you don't directly benefit from. Are there things that you're watching that are of concern, or is it more just that general sense of ebb and flow on births that happen sometimes in economic ups and downs?

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

It's not because of that specifically or anything specific. I would say that right now, my view, it's not a partisan view, is that there are a lot of changes that are swirling in the economy and through the administration, and we don't know how they'll fall out. There are a lot of things that are being considered in the budget today, but there'll be a lot of horse trading, and we'll see how things work out. I just think it's a more difficult economic time when, because of that uncertainty, we all hope it'll work out well. In a time like that, I think it's harder to say with the same clarity where we think we'll end up. Nothing more than that.

[A.J. Rice, Managing Director at UBS]

Okay. All right. Thanks a lot.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Sure. Thank you.

[Operator]

Yes, sir. Your next question comes from the line of Pito Chickering with Deutsche Bank. Your line is open.

[Pito Chickering, Analyst at Deutsche Bank]

Hey, good morning, guys. Mark, good talking to you again. Can you talk about the hospital contracted sort of subsidies? If we go back to sort of pre-COVID, did hospitals get any subsidies? Are they getting subsidies today? Just sort of talk about that dynamic in your business.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Yeah, subsidies have always been part of the business, and they continue to be part of being a partner with a hospital is working together to figure out what's best. If we're a good partner, then subsidies, in many times, are called into play. We have a very good relationship with our hospital system, so that's just part of the overall relationship that we have. It's normal business. Nothing's changed.

[Pito Chickering, Analyst at Deutsche Bank]

Have the amount of subsidies been increasing in the last year or so, or are they as percent of your sort of total revenue still relatively flat?

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

We don't break it out separately, but I'd say that there's no—if there was a notable change, we probably would say it.

[Pito Chickering, Analyst at Deutsche Bank]

Okay. Fair enough. Sort of to A.J.'s question around just guidance for the year, looking at seasonality, is there anything different this year that we should think about from seasonality, whether it's what you guys see in the pipeline or as you think about sort of payer mix changes that would impact seasonality, or should we be expecting a fairly normal seasonality as you look at sort of first quarter EBITDA as percent of what your normal? Is there any reason why that would be different this year versus other years?

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

No, we don't see any different seasonality in 2025. Some of the things that you mentioned that AJ mentioned that we're looking at, it's not that we're forecasting a change or concerned about a change that would affect 2025 numbers. We just don't know yet.

[Pito Chickering, Analyst at Deutsche Bank]

Okay. Right. The last one here is collections. You're looking at the DSOs, those sort of continue to sort of be better, but they're still sort of elevated levels. I guess when you look at the aging of the buckets within those receivables, are there any areas there that could be at risk for taking charges, or are collections continuing to improve across the board and ensure there's no risk of collections at this point looking at your receivables?

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

I'll let our collector in chief answer that call.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Hey, Pito. No, we do not see anything that concerns us there from a DSO or AR in certain buckets. Again, like you said, DSO was flat right around 48 days, and that is actually a level we think makes a lot of sense for the business right now. Everything is going well in the RCM area, and we hope at some point not to have to talk about it every quarter.

[Pito Chickering, Analyst at Deutsche Bank]

Great. Thank you so much, guys. Nice job.

[Operator]

Thanks. Your next question comes from the line of Jack Slevin with Jefferies. Your line is open.

[Jack Slevin, VP and Equity Research Analyst at Jefferies]

Hey, good morning. Thanks for taking the questions, and congrats on a really strong quarter. Just wanted to see if you could expand with a little more color on the points you brought up around potential hospital contract wins. It feels like it's been a pretty static market, although you've been clear that that's the focus. I guess just trying to understand maybe a little bit more about within some of those conversations, what do they look like? Is there a potential that we could see an acceleration in hospitals looking to outsource in light of a lot of challenges they're facing on other fronts, whether it be regulatory or fundamental right now? Thanks.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Our belief is that our strength from the beginning, and no pride of authorship here, has been to be the best partner for hospitals in women's and children's services, where we're very strong. I think we believe that by really focusing on those relationships, it can ensure that we are really reliable counterparties, that we're working on issues, positive issues, and accentuating them and problems and nipping them in the bud, that we're very good at that. What we're talking about doing is focusing on those areas. Also, to have a good partnership, you have to be a very good recruiter. We are only our people. We think there again, if we focus on that, that gives us additional strength.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

We believe, obviously, that if we are the best in women's and children's services, and we focus on both these areas, that we believe we will gain from that. We will grow because of that, because we think hospital systems will say, "Gee, why would we do this ourselves when we can work with a partner that's as reliable as they are that provides the best in class service for women and children and babies?

[Jack Slevin, VP and Equity Research Analyst at Jefferies]

Got it. Really helpful color. Just a couple of things to close the loop on the model here for you, Kasandra. Just on the understanding sort of moving pieces on the dispositions, but that practice applies in other operating expense lines flagged as being quite low, I guess, relative to what I was expecting, I think what Sri was expecting. I guess, is that the right level to think about going forward as we cast things, or is there any additional color you can give on that metric? The other piece just being, can you talk a little bit about the components of the NICU volume growth and what sort of births and length of stay look like in the quarter? Thanks.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Sure. First, on the supplies and other, I think that, yeah, that reflects the practice disposition activity, and it is a good way to look about that line going forward. Nothing material that should flex there. On the NICU staff, yeah, NICU days, of course, were up 2%. Births were also up just over 2%. Of course, those births are just in the hospitals in which we provide services. I'd say admits were up just a touch, probably less than 1% there. Length of stay was also up just a touch, maybe just a touch over 1%. The admit rate itself was a bit flattish in the mid-14% range.

[Jack Slevin, VP and Equity Research Analyst at Jefferies]

Got it. Very helpful. Congrats again on a strong quarter.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Thanks very much.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Thanks, Jack.

[Operator]

Again, if you would like to ask a question, press star one on your telephone keypad. Your next question comes from the line of Pito Chickering with Deutsche Bank. Your line is open.

[Pito Chickering, Analyst at Deutsche Bank]

I think I can let you guys get away with this being over this early. I guess, can you guys sort of give us an update on sort of where we are on the divestitures? I guess, how is it tracking? As you're looking at your portfolio today, are you guys comfortable with the assets you have today? Do you see potential for other areas to divest? As you look at the acquisition market, are you seeing multiples normalize out? You started deploying capital in terms of doing deals. Can you start talking about both sides of the business? Thank you.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

First, to your timing of your question, we thought we were ahead of projections on ending earlier, but we will answer your question anyway. We are very comfortable with the portfolio that we have. Now, any organization that manages well is always looking at ways to optimize what we do, but we are very pleased with the broad restructuring that we did, and it accomplished what we hoped it would do. We will continue to look and try to always find ways to improve what we're doing, but we do not foresee anything sweeping. Certainly, the core areas of neonatology and maternal-fetal medicine, OB hospitals, and pediatric intensive care, they are all part of our core, and none will disappear. We also have in select areas some hospital subspecialties that are also very important to us. We do not see any change there.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

I think there was another part of your question.

[Pito Chickering, Analyst at Deutsche Bank]

Oh, on multiple.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Yeah. Yeah, multiple acquisitions, we think it's a relatively favorable environment for us as an acquirer. I think maybe it's a result of all this turbulence, and maybe it's because other people don't have the kind of balance sheet that we have. They're not able to do what we can do. We think that will provide some opportunities.

[Pito Chickering, Analyst at Deutsche Bank]

That's sort of kind of what I was sort of leaning into as I think about all the headlines coming out of D.C. around Medicaid cuts and the business being such a Medicaid-focused business that wouldn't now be a pretty great time for any weekends to sell into you guys and you guys could take advantage of that sort of near-term volatility.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Could be. Could be. Our phone lines are open.

[Pito Chickering, Analyst at Deutsche Bank]

Okay. Last, a quick mild question. Investments in other income was quite strong this quarter, I guess. What drove that, and how should we be thinking about that for the rest of the year? Thank you so much.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Sure. That is really from the interest income that we're earning on that cash that sat in our balance sheet. We have those parked in pretty attractive rate vehicles right now. As we continue to build cash and continue to earn interest income, that line will look favorable.

[Pito Chickering, Analyst at Deutsche Bank]

Great. Thanks so much.

[Mark Ordan, Chair of Board of Directors and CEO at Pediatrix Medical Group]

Thank you.

[Kasandra Rossi, EVP, CFO, and Treasurer at Pediatrix Medical Group]

Thanks, Pito.

[Operator]

Thank you. I'm not showing any further questions in the queue. Gentlemen, that concludes today's call. Thank you all for joining. You may now.

Participants

Executives

• Mark Ordan, Chair of Board of Directors and CEO
• Kasandra Rossi, EVP, CFO, and Treasurer

Analysts

• A.J. Rice, Managing Director at UBS
• Jack Slevin, VP and Equity Research Analyst at Jefferies
• Pito Chickering, Analyst at Deutsche Bank